I am not quite sure if I believe the pps will drop like a rock with average B data. It did with A, but A failed.
Overall, everything with sppi is fine. If B does not work out, I am not changing my view on the company. I will admit, we could really use positivt results. Not only for caqncer patients, but for sppi and topo as well. If this becomes approved sppi will get the attention needed for stronger pps/volume.